Paradigm Biocapital Advisors LP Autolus Therapeutics PLC Transaction History

Paradigm Biocapital Advisors LP

  • $2.77 Billion
  • Q3 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024
SELL
$5.39 - $7.29 $33.3 Million - $45.1 Million
-6,185,532 Reduced 49.05%
6,425,803 $41 Million
Q4 2023

Feb 14, 2024
SELL
$2.13 - $6.63 $3.82 Million - $11.9 Million
-1,795,447 Reduced 12.46%
12,611,335 $81.2 Million
Q3 2023

Nov 14, 2023
BUY
$2.32 - $3.36 $12 Million - $17.4 Million
5,189,632 Added 56.3%
14,406,782 $33.6 Million
Q2 2023

Aug 14, 2023
BUY
$1.64 - $3.21 $15.1 Million - $29.6 Million
9,217,150 New
9,217,150 $21.9 Million

Others Institutions Holding AUTL

# of Institutions
104
Shares Held
163M
Call Options Held
2.8K
Put Options Held
13.4K
View Full List

About Autolus Therapeutics plc

AUTL Quotes by TradingView
  • Ticker AUTL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 90,909,800
  • Market Cap $208M
  • Description
  • Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which...
More about AUTL
Track This Portfolio

Track Paradigm Biocapital Advisors LP Portfolio

Follow Paradigm Biocapital Advisors LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Paradigm Biocapital Advisors LP, based on Form 13F filings with the SEC.

News

Stay updated on Paradigm Biocapital Advisors LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email